Biohaven presents preclinical data demonstrating taldefgrobep alfa reduces fat and improves lean mass at the obesity society's annual meeting, obesityweek®

- taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including obesity. - taldefgrobep monotherapy significantly reduced fat and increased lean muscle mass in an obese mouse model; potential body composition changes relevant to individuals living with overweight and obesity.
BHVN Ratings Summary
BHVN Quant Ranking